Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsMarion McCourt has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on October 30, 2026. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes George D. Yancopoulos, M.D., Ph.D. (Chairman), Leonard S. Schleifer, M.D., Ph.D. (Chairman), Joseph J. LaRosa (General Counsel) and 7 others.
“Our third quarter results reflect strong commercial execution across our portfolio, with our largest brands achieving new all-time highs in net sales.”
“And I'll share, we share a great ambition for Depixent. The $25 billion was obviously independent guidance given by Sanofi.”
“The fourth quarter delivered a strong finish to 2025, completing a successful year across our commercial portfolio. Our market-leading brands, IDHD, Depixen, and Liptaio continue to deliver sustainable growth based on their clinical profiles as well as our ability to execute effectively in competitive markets.”
Source not stated
Biotechnology · Healthcare
